Bio

Mr. Hill is an Operating Partner of Arsenal for the healthcare team. Prior to joining Arsenal in 2023, he was the Chairman and CEO of CorEvitas, a leader in providing real-world evidence to assess the safety and clinical effectiveness of therapies in autoimmune and inflammatory-medicated diseases. Over a nine-year period leading CorEvitas, he oversaw significant growth and two recapitalization events, the most recent of which was the acquisition of CorEvitas by Thermo Fisher Scientific. Prior to CorEvitas, Mr. Hill was President of InVentive Clinical (now Syneos Health), a leading clinical research organization. He also served as President of IMS Health (now IQVIA) from 2003 to 2011. Earlier in his career he was a Partner and led A.T. Kearney’s pharmaceutical and healthcare practice globally. M.E.M., Duke University; B.S., Cornell University;